Risk Factors Associated With the Global Burden of Disease in Reunion Island and Comparison With Mainland France and Indian Ocean Countries (AVIRON-2)

The question posed by this project is that of the regional estimate of the relative importance of the risk factors of the main pathologies. Our hypothesis is that these risk factors are of different relative importance in Reunion Island compared to metropolitan France.

Study Overview

• Status: Completed
• Conditions: Disability or Chronic Disease Leading to Disablement

Detailed Description

The definition of health priorities in a given territory is a major field of Public Health research. The World Health Organization has been conducting the Global Burden of Disease study since the 1990s. This study, which has been the subject of numerous publications, aims at estimating the burden for a given population of different causes of mortality and morbidity. It defines a standardized measure allowing comparisons between different countries. The measure developed internationally is the "Disability-adjusted life year" (DALY). This also allows the monitoring of the relative importance of each pathology. This standardized classification of the relative importance of the pathologies and risk factors involved is a major public health tool.

This measure was developed at the international level initially and then recently applied locally (London neighborhoods, US states). For the Indian Ocean zone, DALY values are available for Madagascar, Seychelles and Mauritius. The estimate of this measure for Reunion Island is based on data from metropolitan France. It therefore uses for Reunion mortality, morbidity, income per capita and social indicators of metropolitan France. It does not take into account the specificities of Reunion. In order to better understand Reunion's public health priorities, it seems important to decline this measure at the regional level. The implementation of this measure at the regional level corresponds to the research project AVIRON which aimed at collecting all the data for the calculation of the DALY in Reunion Island. The AVIRON-2 study, which extends AVIRON's focus on morbidity and mortality, will aim at determining the attributable part of the various disease risk factors and to classify these risk factors according to their importance in a given population for all diseases.

• Study Type: Observational
• Enrollment (Actual): 100000

Contacts and Locations

Study Locations

• France
  • Reunion
    • Saint Pierre Cedex, Reunion, France, 97448
      • Olivier MAILLARD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Population living in Reunion Island

Description

Inclusion Criteria:

The whole population living in Reunion Island

Exclusion Criteria:

People not living in Reunion Island

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quantity of DALY lost for each risk factor	Risk factors associated to the most prevalent diseases	2 months after legal and ethical agreements

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de la Réunion
• Investigators: Study Director: Laetitia Huiart, MD, Luxembourg Institute of Health

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2017
• Primary Completion (Actual): April 30, 2018
• Study Completion (Actual): April 30, 2018

Study Registration Dates

• First Submitted: November 24, 2017
• First Submitted That Met QC Criteria: November 24, 2017
• First Posted (Actual): November 29, 2017

Study Record Updates

• Last Update Posted (Actual): September 6, 2018
• Last Update Submitted That Met QC Criteria: September 4, 2018
• Last Verified: September 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Chronic Disease
• Other Study ID Numbers: 2016/CHU/15

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No